Please login to the form below

Not currently logged in
Email:
Password:

Avillion names Allison Jeynes-Ellis CEO

Her career to date includes experience at ABPI, J&J, Roche, Wyeth, BMS and Novartis

Avillion, Allison Jeynes EllisAvillion has appointed the well-travelled and experienced Dr Allison Jeynes-Ellis as the company's new CEO.

Jeynes-Ellis has spent time at several major pharma companies in her 22-year career in the industry, including senior roles at Roche, Genentech Wyeth (now Pfizer), Bristol-Myers Squibb, Novartis, Nycomed and trade body the Association of the British Pharmaceutical Industry (ABPI).

These includes medical director positions and specific oncology positions and she also has consultancy experience at Johnson & Johnson and AstraZeneca.

Most recently Jeynes-Ellis was chief medical officer at Avillion, a UK-based company she co-founded in 2011 to focus on the co-development and financing of late-stage drug candidates.

She will now lead Avillion as it prepares to advance its first collaborative development agreement with Pfizer to conduct a global phase III clinical trial evaluating Bosulif (bosutinib) as a first-line treatment in chronic myelogenous leukaemia.

Kurt Wheeler, a non-executive director of Avillion, said: “We are confident that, under Allison's leadership, this agreement will be the first of several that Avillion signs over the coming years.”

19th February 2014

From: Research, Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Visformatics (VISFO)

A team of strategic decision specialists with over 30+ years in the pharma space, we give you confidence through experience....

Latest intelligence

What does HCP engagement look like in a post-Covid world?
HCP engagement has changed as a result of the Covid-19 pandemic, with pharmaceutical companies and agencies having to rapidly adjust to a new way of communicating. Digital channels have become...
Menopause-thumbnail.png
Breaking the silence: It’s time to talk about the menopause
Using findings from our latest opinion poll, Vicki Newlove outlines why the hidden landscape of menopause may finally be starting to change....
Committing time to making meaningful connections - top 5 tips
Read the second blog of the series looking at key barriers to effective patient engagement in pharma...